Oakmont Advisory Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Oakmont Advisory Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$294	Buy	+1	New	+$284	﹤0.01%	491

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Oakmont Advisory Group's BIO Position: Q2 2026 in Review

Oakmont Advisory Group opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 1 share worth $294. The stake represents ﹤0.01% of the portfolio and ranks #491 among its holdings.

395 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Oakmont Advisory Group held 1 share of Bio-Rad Laboratories Class A worth $294 as of Q2 2026.
Bio-Rad Laboratories Class A was a new Oakmont Advisory Group position in Q2 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Oakmont Advisory Group's portfolio in Q2 2026, its #491 holding.
395 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Oakmont Advisory Group's 13F filing for Q2 2026, filed 3 Aug 2026.